<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8918110</journal-id>
<journal-id journal-id-type="pubmed-jr-id">2607</journal-id>
<journal-id journal-id-type="nlm-ta">Eur J Neurosci</journal-id>
<journal-id journal-id-type="iso-abbrev">Eur. J. Neurosci.</journal-id>
<journal-title-group>
<journal-title>The European journal of neuroscience</journal-title>
</journal-title-group>
<issn pub-type="ppub">0953-816X</issn>
<issn pub-type="epub">1460-9568</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27520881</article-id>
<article-id pub-id-type="pmc">5209277</article-id>
<article-id pub-id-type="doi">10.1111/ejn.13357</article-id>
<article-id pub-id-type="manuscript">NIHMS811710</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Lohr</surname>
<given-names>Kelly M.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="author-notes" rid="FN2">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Masoud</surname>
<given-names>Shababa T.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="author-notes" rid="FN2">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Salahpour</surname>
<given-names>Ali</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Miller</surname>
<given-names>Gary W.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A4">4</xref>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Department of Environmental Health, Rollins School of Public Health, Emory University, Atlanta, GA 30322</aff>
<aff id="A2"><label>2</label>Department of Pharmacology and Toxicology, University of Toronto, Ontario M5S 1A8, Canada</aff>
<aff id="A3"><label>3</label>Center for Neurodegenerative Diseases, Emory University, Atlanta, GA 30322</aff>
<aff id="A4"><label>4</label>Department of Pharmacology, Emory University, Atlanta, GA 30322</aff>
<aff id="A5"><label>5</label>Department of Neurology, Emory University, Atlanta, GA 30322</aff>
<author-notes>
<corresp id="FN1">Mailing address: 1518 Clifton Road, Rollins School of Public Health, Atlanta, GA 30322, USA, Phone number: 404-712-8582, <email>gary.miller@emory.edu</email></corresp>
<fn fn-type="equal" id="FN2">
<label>*</label>
<p>equal contribution</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>13</day>
<month>9</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>02</day>
<month>9</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<month>1</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>1</month>
<year>2018</year>
</pub-date>
<volume>45</volume>
<issue>1</issue>
<fpage>20</fpage>
<lpage>33</lpage>
<!--elocation-id from pubmed: 10.1111/ejn.13357-->
<abstract>
<p id="P1">Dopamine was first identified as a neurotransmitter localized to the midbrain over 50 years ago. The dopamine transporter (DAT; SLC6A3) and the vesicular monoamine transporter 2 (VMAT2; SLC18A2) are two regulators of dopamine homeostasis in the presynaptic neuron. DAT transports dopamine from the extracellular space into the cytosol of the presynaptic terminal. VMAT2 then packages this cytosolic dopamine into vesicular compartments for subsequent release upon neurotransmission. Thus, DAT and VMAT2 act in concert to move transmitter efficiently throughout the neuron. The accumulation of dopamine in the neuronal cytosol can trigger oxidative stress and neurotoxicity, suggesting that the proper compartmentalization of dopamine is critical for neuron function and risk of disease. For decades, studies have examined the effects of reduced transporter function in mice (e.g. DAT-KO, VMAT2-KO, VMAT2-deficient). However, we have only recently been able to assess the effects of elevated transporter expression using BAC transgenic methods (DAT-tg, VMAT2-HI mice). Complemented with in vitro work and neurochemical techniques to assess dopamine compartmentalization, a new focus on the importance of transporter proteins as both models of human disease and potential drug targets has emerged. Here we review the importance of DAT and VMAT2 function in the delicate balance of neuronal dopamine.</p>
</abstract>
<kwd-group>
<kwd>dopamine</kwd>
<kwd>DAT</kwd>
<kwd>VMAT2</kwd>
<kwd>Parkinsonâ€™s disease</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>